PPWR self-assessment

Start now

Seven EU States Seek Reassessment Of Wastewater Producer-Responsibility Costs

Dr Steven Brennan
Dr Steven Brennan
2 min readAI-drafted, expert reviewed
Circular wastewater treatment basins and steel walkways at a European treatment plant

Key takeaway

What This Development Means

Poland and six supporting EU states have called for a fresh assessment of wastewater producer-responsibility costs and possible coordinated deadline changes. Their Council note does not amend the directive. Medicines and cosmetics producers should continue preparing for the existing requirements.

Has the joint request postponed wastewater EPR?

No. The Council note asks the Commission to assess whether coordinated deadline adjustments are needed if the reassessment identifies significant shortcomings or serious consequences. The note itself changes no legal deadline.

Which producers can qualify for an exemption?

Article 9 requires Member States to exempt producers that demonstrate that substances in their products placed on the Union market total less than one tonne a year, or that those substances are rapidly biodegradable in wastewater or do not generate micropollutants at the end of their life. Evidence is required.

Source basis: Council note 14204/26 and Directive (EU) 2024/3019

Joint Request Seeks A New Cost Assessment

Poland, supported by Bulgaria, Estonia, Greece, Italy, Lithuania and Slovakia, has asked the European Commission to reassess extended producer responsibility under the Urban Wastewater Treatment Directive. Their Council note dated 8 October 2026 was prepared for the 12 October Environment Council.

The states want a new independent assessment and a transparent method for attributing micropollutants to sectors. They raise concerns about proportionality, medicine supply and the allocation of treatment costs to pharmaceuticals and cosmetics. They also reaffirm support for advanced treatment and an EPR system.

A Conditional Request Does Not Pause The Law

The note asks the Commission to assess temporary adjustments or suspension of relevant deadlines if reassessment identifies significant shortcomings or serious economic and social consequences. Any pause should cover both EPR and related quaternary-treatment requirements to prevent a funding gap.

The note does not suspend or amend the directive. Under Directive (EU) 2024/3019, national transposition is due by 31 July 2027. Member States must ensure that affected producers have EPR arrangements by 31 December 2028.

Cost Shares And Exemptions Need Careful Reading

Annex III covers human medicinal products and cosmetics within the specified EU legislation. Article 9 requires affected producers to cover at least 80% of the specified quaternary-treatment and micropollutant-monitoring costs. It separately requires coverage of product-data gathering and verification costs and other costs of exercising EPR. These are financing obligations, not penalties.

Member States must exempt producers that demonstrate that substances in their products placed on the Union market total less than one tonne annually. An alternative exemption applies where those substances are rapidly biodegradable in wastewater or do not generate micropollutants at the end of their life.

For producers in scope, contributions are determined using the quantities and hazardousness in wastewater of substances in products placed on the market. The directive requires annual information on quantities, hazardousness, biodegradability and relevant exemptions.

Keep Product Data Work Moving

Foresight analysis. Regulatory and finance teams should continue preparing national implementation plans while monitoring the Commission's response. Build evidence for product quantities and any claimed exemption. Treat the joint request as a reason to track policy developments, rather than a basis for removing expected EPR costs from planning.

Get weekly regulatory updates:

Related Articles

Join 3,500+ professionals staying ahead

Subscribe to Foresight Weekly for expert-picked regulatory developments across chemicals, sustainability, product safety, ESG, and HSE.

Free forever. Unsubscribe anytime.

Read by professionals at

Boeing
AstraZeneca
Siemens
PepsiCo
SpaceX